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Neuroendocrine tumours (NETs) comprise a heterogenous group of malignancies with an often unpredictable course, and with
limited treatment options. Thus, new diagnostic, prognostic, and therapeutic markers are needed. To shed new lights into the biology
of NETs, we have by cDNA transcript profiling, sought to identify genes that are either up- or downregulated in NE as compared
with non-NE tumour cells. A panel of six NET and four non-NET cell lines were examined, and out of 12743 genes examined, we
studied in detail the 200 most significantly differentially expressed genes in the comparison. In addition to potential new diagnostic
markers (NEFM, CLDN4, PEROX2), the results point to genes that may be involved in the tumorigenesis (BEX1, TMEPAI, FOSL1,
RAB32), and in the processes of invasion, progression and metastasis (MME, STAT3, DCBLD2) of NETs. Verification by real time
qRT–PCR showed a high degree of consistency to the microarray results. Furthermore, the protein expression of some of the genes
were examined. The results of our study has opened a window to new areas of research, by uncovering new candidate genes and
proteins to be further investigated in the search for new prognostic, predictive, and therapeutic markers in NETs.
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Neuroendocrine (NE) tumours (NETs) belong to a heterogenous
group of neoplasms arising from malignant transformation of
various types of NE cells (Falkmer, 1993; Wick, 2000; DeLellis,
2001; Hofsli, 2006). Although the majority of NETs are rather slow
growing, their biology is often unpredictable, making their
management a great challenge (Stephenson, 2006; Vilar et al,
2007). Thus, new insight into the biology of these fascinating
tumours could not only make prognostication easier, but also
guide in the selection for the right treatment strategy, and
contribute in the search for new drug targets. This last issue is
of vital importance, as up till now, only surgery has the potential to
cure patients with NET disease.
Prediction of the biological behaviour of NETs may be difficult
based upon histological criteria alone (Wick, 2000; Stephenson,
2006). Well-differentiated NETs are easily recognised by routine
tissue staining and conventional light microscopical (LM)
examination, combined with immunohistochemical (IHC) detec-
tion of NE markers such as chromogranin A (CHGA) and
synaptophysin (SYP). However, dealing with poorly differentiated
tumours, it may be difficult to decide whether a tumour exhibits an
NE character. Thus, new diagnostic markers are warranted.
In addition to classical NETs, it has been increasingly recognised
that both mixed endocrine–exocrine malignant tumours, as well
as NE differentiation in common epithelial cancers, may occur
(Capella et al, 2000; Sørhaug et al, 2007). The picture is even more
complex, as recent research has indicated that use of more
sensitive methods such as the tyramide signal amplification
technique, will identify more NE tumour cells than today’s routine
diagnostic procedures manage to do (Sørhaug et al, 2007). With
respect to prognosis and treatment, the impact of such NE
differentiation in epithelial cancers is mostly unknown.
To shed new lights into the biology of NETs, we have compared
the gene expression pattern of a selection of NE tumour cells, with
that of a group of non-NE tumour cells. By this approach, we have
identified genes that are differentially expressed in NE vs non-NE
tumour cells. We propose that some of the genes and their gene
products may represent interesting new molecular factors with
regard to tumorigenesis, prediction of prognosis and treatment
response, as well as may represent novel therapeutic targets.M
MATERIALS AND METHODS
Cell culture
Six NE and four non-NE cell lines were used in the gene expression
analysis. All cell lines, except the BON cell line, were obtained from
the American Type Culture Collection (ATCC, Manassas, VA,
USA). BON cells (Evers et al, 1991) were a generous gift from
Professor Kjell O ¨berg, Department of Medical Science, Uppsala
University Hospital, Uppsala, Sweden, and cultured as described in
Hofsli et al (2005). The six NE cell lines represent various NETs:
neuroblastomas (SK-N-AS, SK-N-FI), bronchial carcinoids (NCI-
H727, UMC-11), gastrointestinal carcinoid (BON), and medullary
thyroid carcinoma (TT). The non-NE cell lines were colorectal
adenocarcinomas (WiDr, SW480), lung adenocarcinoma (A-427)
and glioblastoma (A-172). All these cell lines were cultured
according to the requirements given by ATCC.
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Cells were cultured in 75cm
2 culture flasks until 80% confluence,
harvested and directly subjected to RNA isolation. Total RNA was
isolated using RNeasy midi kit (Qiagen, Germantown, MD, USA),
according to the manufacturer’s instruction. Two independent
biological experiments were performed with each cell line. The
quality of the RNA was examined by use of Agilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). The
samples were kept frozen at  801C until further processing.
Microarray hybridisation
Human cDNA arrays with 15000 probes in duplicate were
obtained from Norwegian Microarray Consortium, Oslo, Norway
(http://www.microarray.no). These arrays were prepared using
sequence-verified human genes (Research Genetics, Huntsville,
AL, USA). Additional information of cDNA clone preparation and
printing is described in detail within the platform GPL3313, of the
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc¼GPL3313). Two negative controls and ten
different cDNA spike-in controls from Arabidopsis thaliana
(Stratagene SpotReporter, La Jolla, CA, USA) were included in all
arrays. Total RNA (2mg) from the cell lines and from Universal
Human Reference RNA (Stratagene, La Jolla, CA, USA), was
reverse transcribed and labelled with Cy3- and Cy5-attached
dendrimer, respectively, using the Genisphere 3DNA Array 350
Expression Array Detection kit (Genisphere, Montvale, NJ, USA),
as described in the manufacturer’s protocol and previously by us
(Yadetie et al, 2003; Nørsett et al, 2004; Hofsli et al, 2005). To
reduce the artefacts because of different sensitivity to photo-
bleaching, the biologic replicates of each of the 10 cell lines were
randomised by dye-swaps. The arrays were scanned separately by
two wavelengths (532 and 633nm) using ScanArray Express HT
scanner (Packard BioScience, Billerica, MA, USA).
Microarray data analysis
The microarray data were prepared according to the MIAME
recommendations (Brazma et al, 2001). Image analysis was carried
out using the GenePix Pro 4.1 software (Axon Instruments, Union
City, CA, USA). All subsequent statistical analysis was performed
using the statistical package R (R Development Core Team, 2004),
and the LIMMA package from the Bioconduction project (Smyth,
2005). Flawed spots (manually examined) and spots with more
than 40% saturated pixels in any channel were removed from the
analyses. This resulted in the removal of 17–31% of spots for each
array. To compensate for systematic errors each array was
normalised using loess normalisation, and then scaled so that
the log-transformed ratios had the same median absolute deviation
(Yang et al, 2002a,b). Further analyses were based on these
normalised log-transformed ratios for each duplicate gene for the
20 microarrays.
To assess the difference between the NE vs non-NE tumour cells
for each gene, tests for differential expression were performed
using moderated t-tests based on duplicated spots, as implemented
in the Limma R package of Smyth et al (2005). This is based on
empirical Bayes analysis, where the power of the tests is improved
by replacing gene-specific variance estimates with estimates found
by borrowing strength from data on the remaining genes. The
proportion of truly differentially expressed genes was estimated
using the convex decreasing density estimator of Langaas (2005),
and the false discovery rate (FDR) was estimated using the method
of Storey (2002), with the estimated proportion of truly
differentially expressed genes found above inserted.
Cluster analysis was performed as an aid to display the results in
a graphical manner. The analysis was performed on the normalised
log ratios taking the median over duplicate spots for each gene,
and the mean over the dye-swapped replicates. Hierarchical cluster
analysis was based on Pearson correlation and the distance
between the clusters was both computed using the average- and
complete linkage. In addition clustering using the K-means
algorithm (using two clusters) was also performed on a selection
of the most differentially expressed genes.
Real-time qRT–PCR
cDNA synthesis was performed with 500ng total RNA in a 10-ml
reaction containing 1 PCR buffer II, 5mM MgCl2, 500mM each
dNTP, 2.5mM. Oligo d(T)16 primer, 0.4U/ml RNase inhibitor
and 2.5U/ml MuLV Reverse transcriptase (Applied Biosystems,
Mannheim, Germany). cDNA synthesis was performed at 10min
at 251C followed by 1h at 481C and 5min at 951C. Design of
PCR primers and probes was performed using Primer3 (version
0.2, online software) (http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3_www.cgi) and the mRNA sequences obtained using the
NCBI RefSeq accession numbers of the respective genes (Table 1).
All primers and probes were delivered from Eurogentec, Seraing,
Table 1 Primers and probes
Symbol/gene Bank Accession No. Sequence (50-30) Forward reverse probe Product length
BAALC actgcccatggcatgtct S 66
NM_024812 tccaggcagatgaggagc AS
tgggaggtgtctgtgaagcagtca Probe
FOSL1 accctcagtacagccccc F 81
NM_005438 aaggccttcgacgtaccc AS
aaccccggccaggagtcatc Probe
GSTP1 tgcctatacgggcagctc F 102
NM_000852 cccatagagcccaagggt AS
aagttccaggacggagacctcacc Probe
SCG2 tggctgaagcaaagaccc F 75
NM_003469 cagccccagagatgagga AS
tggagcagccctgtctcttatccc Probe
M160 tctatcacgacggcttct F 174
NM_174941 ccattcctgtgcagttca AS
aatgccacggtctctgctcacttt Probe
GAPD F
NM_002046 AS
Probe
Genes, primers, and probe sequences of selected genes for confirmation studies. The length, product length, and orientation are given here.
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681C, respectively. TaqMan real-time PCR was performed with
1 Quantitect Probe PCR Master Mix (Qiagen, Germantown, MD,
USA), 400nM of each primer, 200nM TaqMan Probe (Eurogentec)
or sybergreen and cDNA equivalent to 62.5ng total RNA in a total
reaction volume of 25ml. The Real-Time PCR was performed in
Stratagene’s Mx3000P Real Time PCR system; 15min at 951C, 40
thermal cycles of 15s at 941C, 30min at 561C and 30s at 761C. Each
sample was measured in triplicate. A negative control without the
cDNA template was included, and contamination by genomic DNA
was ruled out by performing PCR analysis on template where
reverse transcriptase had been omitted in the RT reactions.
GAPDH was run in parallel as controls to monitor RNA integrity
and to be used for normalisation. Fold induction of gene
expression level was estimated by the DDCt-method, where: Fold
change¼2
 DDCt and DDCt¼(CtGOI CtGAPDH)untreated (CtGOI 
CtGAPDH)treated (Livak and Schmittgen, 2001). This was accom-
plished by using the same universal human reference RNA in both
the microarray and the real-time RT–PCR analysis;
2 ðCtGENX CtGAPHDÞcellline ðCtGENX CtGAPHDÞHumRef
Western blot
Whole cell lysates were prepared from 5–7 10
6 cells which were
washed two times in PBS, scraped and harvested directly in 2000ml
SDS-sample buffer (62.5mM Tris-HCl, pH 6.8; 8.7% glycerol; 2% w/v
SDS; 5% v/v 2-b mercaptoethanol; 0.09% w/v bromophenol blue).
Viscosity was reduced by drawing the suspension through a 21-G
needle, cell debris were removed by centrifugation (15000g,
10min), and the supernatant was stored at  801C. Each extract
(15ml) was boiled and separated on an SDS 10% polyacrylamide
gel (running buffer: 25mM Tris-HCl, pH 8.3; 190mM glycine, 0.1%
w/v SDS) before electrotransfer onto Hybond-P membranes
(Amersham Pharmacia Biotech, Pittsburgh, PA, USA). The transfer
was performed in 25mM Tris-HCl, 190mM glycine and 20%
methanol, pH 8.3, for 1h at 175mA. The membranes were treated
with 5% nonfat dry milk (Nestle ´, Vevey, Switzerland) in TBS
(50mM Tris-HCl, pH 7.5 and 150mM NaCl) for 1h at room
temperature and incubated with primary antibodies diluted
(1:500–1:1000) in TBS with 1% BSA and 0.05% Tween 20 for
2h, 201C. The blots were then incubated with peroxidase-
conjugated secondary antibodies (1:1000) in TBS with 1% BSA
and 0.05% Tween 20 for 1h at room temperature. After
washing (4 15min in TBS with 0.05% Tween 20), binding of
secondary antibodies was visualised by the ECL-detection system
(Amersham) before they were digitally exposed with the KODAK
Image Station 2000R (Kodak, Rochester, NY, USA) for 5min.
GAPDH levels were used to verify protein loading.
The following antibodies were used: mouse anti-human GAPDH
(1:1000) (Abcam, Cambridge, UK), mouse anti-human PRDX2
(1:1000) (Abcam), rabbit anti-human HPN (1:1000) (Cayman,
Michigan, USA), rabbit anti-human SCG2 (1:500) (Abcam) and a
secondary antibody conjugated to horseradish peroxidase (Pierce,
Rockford, IL, USA).
Immunohistochemical and ultrastructural examinations
For IHC investigations, cell pellet was conventionally fixed in 10%
neutral formalin, dehydrated, and embedded in paraffin. Sections,
about 4–5 micron thick, were employed for the IHC examinations,
using the Vectastain ABC kit (Vector Lab., Burlingame, CA, USA),
and/or Tyramide signal amplification technique (NEN LifeScience
Products, Boston, MA, USA), as previously described (Qvigstad
et al, 1999). Chromogranin A antiserum (1:500) was provided by
Incstar (Stillwater, MN, USA), monoclonal mouse antisynapto-
physin antiserum (1:20) by Dako (Glostrup, Denmark), anti rat
neuron-specific enolase (1:500) by Polysciences (Warrington, PA,
USA), and antineurofilament M (1:4000) by Fitzgerald (MA, USA).
For the electron microscopic (EM) investigations, the pellet was
fixed in 2% neutral glutaraldehyde, post-fixed in 2% osmium
tetroxide, contrasted with 1% lead citrate and 4% uranyl acetate,
and conventionally embedded in Epon. Finally, conventional ultra
thin sections were cut and analysed by means of our transmission
EMs (JEOL 100CX and Phillips SEI Tecnai 12).
RESULTS
Confirmation of the NE character
To confirm the NE and non-NE character of the cell lines,
respectively, IHC and EM investigations were performed in
addition to conventional LM examination. The employed NE cell
lines (NCI-H727, UMC-11, SK-N-AS, SK-N-FI, TT, BON) encom-
pass NE features with the expression of CHGA and SYP as the
confined NE marker. The four cell lines known to be of non-NE
character (WiDr, A-172, A-427, SW480), showed no staining with
CHGA and SYP (data not shown). In addition, the cells were
examined for the expression of ENO2 (enolase 2/neuron-specific
enolase), an NE marker thought to be less specific than the
conventional NE markers CHGA and SYP. All the presumed NE
cell lines showed positive immunoreactivity to enolase 2, and this
was also the case for the non-NE cell lines A-427 and SW480 (data
not shown). EM investigations demonstrated occurrence of typical
NE secretion granules in all the NE tumour cells, but not in any
of the non-NE tumour cells, thus confirming the predefined
NE/non-NE characteristics of the cell lines used.
Genes differentially expressed in NE vs non-NE tumour
cells
Having confirmed the NE and non-NE character of the cell lines,
respectively, we performed transcript profiling by cDNA micro-
array analysis in an effort to identify new NE-specific genes, and by
this, get more insight into the biology of NETs.
By using the convex decreasing density estimator for the
proportion of true null hypotheses as presented in Langaas (2005),
we expect 5.5% of the genes studied to be differentially expressed
in NE vs non-NE cells. The 200 most significant genes (P-value
0.008/FDR 0.49) in the comparison of the NE vs non-NE tumour
cell groups are sequence verified, and 153 genes are given as
Supplementary Information in the gene expression omnibus
(GEO) GSE4328.
Based on information from the GO annotation database and
literature search, these genes are displayed with the log ratio and
biological processes in which they are likely to be involved. The
up- and downregulated genes range from log2 5.87 to  2.92,
respectively. The 70 most highly up- and downregulated genes, are
shown in Table 2. A hierarchical cluster analysis of the 48 most
significantly differentially expressed genes (P-value 0.0014/FDR
0.2823) are shown in Figure 1.
The three most highly overexpressed genes: SCG3 (26.6 fold),
SCG2 (15.3 fold) and DDC (9.6 fold) (Table 2), have previously
been shown to be linked to NE tumour biology, thus confirming
the reliability of our study design. SCG3 and SCG2 are both
members of the chromogranin–secretogranin family of NE
secretory, acidic glycoproteins (Taupenot et al, 2003), and DDC
has more recently been shown to be expressed in various NETs
(Uccella et al, 2006). Furthermore, the high expression of MAOA in
our study, support previous findings of high expression of
monoaminoxidase A in various NETs (O ¨rlefors et al, 2003).
NETs in general are relatively slow growing tumours with a less
invasive character than many epithelial cancers. Several genes
thought to play a role in the processes of invasion, tumour
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sTable 2 Differentially expressed genes in NE vs non-NE tumour cells
Gene symbol Gene name UGCluster Ratio
Upregulated
SCG3 Secretogranin III Hs.232618 26.56
SCG2 Secretogranin II (chromogranin C) Hs.516726 15.29
DDC Dopa decarboxylase (aromatic L-amino acid decarboxylase) Hs.359698 9.65
BAALC Brain and acute leukaemia, cytoplasmic Hs.533446 7.78
NEF3 Neurofilament 3 Hs.458657 7.66
C8orf13 Chromosome 8 open reading frame 13 Hs.124299 7.27
BEX1 Brain expressed, X-linked 1 Hs.334370 6.76
RAPGEF5 Rap guanine nucleotide exchange factor (GEF) 5 Hs.174768 6.01
PLXNA2 Plexin A2 Hs.497626 5.88
Hypothetical LOC90024 Hs.534513 5.30
MGC17299 Hypothetical protein MGC17299 Hs.104476 5.11
PRDX2 Peroxiredoxin 2 Hs.432121 5.04
M160 Scavenger receptor cysteine-rich type 1 protein M160 Hs.49636 5.01
DNAJC12 DnaJ (Hsp40) homologue, subfamily C, member 12 Hs.260720 4.50
MAOA Monoamine oxidase A Hs.183109 4.48
FAM46A Family with sequence similarity 46, member A Hs.10784 4.29
FNDC5 Fibronectin type III domain containing 5 Hs.524234 4.11
CLDN4 Claudin 4 Hs.520942 3.96
CACNA1H Calcium channel, voltage-dependent, a 1H subunit Hs.459642 3.95
ITGA10 Integrin, a 10 Hs.158237 3.88
HLA-DOA Major histocompatibility complex, class II, DO a Hs.351874 3.70
CNTN1 Contactin 1 Hs.143434 3.65
NR0B2 Nuclear receptor subfamily 0, group B, member 2 Hs.427055 3.57
TAGLN3 Transgelin 3 Hs.169330 3.45
PEG10 Paternally expressed 10 Hs.147492 3.37
EGLN3 Egl nine homologue 3 (C. elegans) Hs.135507 3.36
MBP Myelin basic protein Hs.551713 3.36
ABCC6 ATP-binding cassette, subfamily C (CFTR/MRP), member 6 Hs.13188 3.26
SFMBT2 Scm-like with four mbt domains 2 Hs.407983 3.21
C9orf150 Chromosome 9 open reading frame 150 Hs.445356 3.17
CDNA FLJ37828 fis, clone BRSSN2006575 Hs.123119 3.15
HIPK2 Homeodomain interacting protein kinase 2 Hs.397465 3.10
CDNA FLJ45289 fis, clone BRHIP3002363 Hs.556782 3.08
C17orf28 Chromosome 17 open reading frame 28 Hs.11067 3.05
C3orf14 Chromosome 3 open reading frame 14 Hs.47166 2.94
LIMD1 LIM domains containing 1 Hs.193370 2.92
HPN Hepsin (transmembrane protease, serine 1) Hs.182385 2.82
MDS010 x 010 protein Hs.231750 2.77
MS4A1 Membrane-spanning 4-domains, subfamily A, member1 Hs.438040 2.75
NAPB N-ethylmaleimide-sensitive factor attachment protein, b Hs.269471 2.69
PBX1 Pre-B-cell leukaemia transcription factor 1 Hs.493096 2.63
APG4A APG4 autophagy 4 homologue A Hs.8763 2.60
ARHGAP26 Rho GTPase-activating protein 26 Hs.293593 2.56
GAB2 GRB2-associated binding protein 2 Hs.429434 2.53
AQP3 Aquaporin 3 Hs.234642 2.45
MGC4645 Hypothetical protein MGC4645 Hs.395306 2.44
PTP4A3 Protein tyrosine phosphatase type IVA, member 3 Hs.43666 2.40
TP53I11 Tumour protein p53-inducible protein 11 Hs.554791 2.36
Clone IMAGE:121214 mRNA sequence Hs.283883 2.36
C14orf132 Chromosome 14 open reading frame 132 Hs.6434 2.33
SC5DL Sterol-C5-desaturase Hs.287749 2.29
CENTB5 Centaurin, b 5 Hs.535257 2.15
ARHGAP5 Rho GTPase-activating protein5 Hs.525287 2.13
KIAA0924 KIAA0924 protein Hs.560561 2.10
C6orf1 Chromosome 6 open reading frame 1 Hs.381300 2.10
SGTB Small glutamine-rich tetratricopeptide repeat (TPR) Hs.287971 2.05
NNT Nicotinamide nucleotide transhydrogenase Hs.482043 2.05
BRPF3 Bromodomain and PHD finger containing, 3 Hs.520096 1.99
TBC1D16 TBC1 domain family, member 16 Hs.369819 1.98
IRF2BP2 Interferon regulatory factor 2-binding protein 2 Hs.350268 1.94
DKFZp434H2226 LMBR1 domain containing 2 (DKFZp434H2226) Hs.294103 1.93
CALM1 Calmodulin 1 (phosphorylase kinase, delta) Hs.282410 1.82
C6orf209 Chromosome 6 open reading frame 209 Hs.271643 1.79
ZCCHC3 Zinc finger, CCHC domain containing 3 Hs.28608 1.78
IRS2 Insulin receptor substrate 2 Hs.442344 1.76
RGS18 Regulator of G-protein signalling 18 Hs.440890 1.70
SCFD1 Sec1 family domain containing1 Hs.369168 1.69
TCEAL8 Transcription elongation factor A (SII)-like 8 Hs.389734 1.67
SEC23B Sec23 homologue B (S. cerevisiae) Hs.369373 1.59
MECP2 Methyl CpG-binding protein 2 Hs.200716 1.59
Downregulated
MME Membrane metallo-endopeptidase Hs.307734 0.12
STAT3 Signal transducer and activator of transcription 3 (acute-phase response factor) Hs.463059 0.13
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Gene symbol Gene name UGCluster Ratio
MEOX1 Homeobox protein MOX-1 Hs.438 0.14
TMEPAI Transmembrane, prostate androgen induced RNA Hs.517155 0.15
RAB32 RAB32, member RAS oncogene family Hs.287714 0.17
KLF2 Kruppel-like factor 2 (lung) Hs.107740 0.17
ZNF354A Zinc finger protein 354A Hs.484324 0.17
LOC255104 Hypothetical protein LOC255104 Hs.466729 0.18
S100A10 S100 calcium-binding protein A10 (annexin II ligand, calpactin I, light polypeptide (p11)) Hs.143873 0.18
DCBLD2 Discoidin, CUB and LCCL domain containing 2 Hs.203691 0.18
HSPC016 Hypothetical protein HSPC016 Hs.356440 0.20
USP4 Ubiquitin-specific peptidase 4 (proto-oncogene) Hs.77500 0.21
GSTP1 Glutathione S-transferase pi Hs.523836 0.22
AKAP12 A kinase (PRKA) anchor protein (gravin) 12 Hs.371240 0.23
MGC7036 Hypothetical protein MGC7036 Hs.488173 0.24
ZF HCF-binding transcription factor Zhangfei Hs.535319 0.25
AMOTL2 Angiomotin like 2 Hs.426312 0.25
LMO2 LIM domain only 2 Hs.34560 0.25
CETN2 Centrin, EF-hand protein, 2 Hs.82794 0.27
RUNX1 Runt-related transcription factor 1 (acute myeloid leukaemia 1; aml1 oncogene) Hs.149261 0.27
HRASLS3 HRAS-like suppressor 3 Hs.502775 0.28
APEH N-acylaminoacyl-peptide hydrolase Hs.517969 0.28
ERBB2 V-erb-b2 erythroblastic leukaemia viral oncogene homologue 2, neuro/glioblastoma derived oncogene homologue Hs.446352 0.28
YAP1 Yes-associated protein 1, 65kDa Hs.503692 0.31
CD9 CD9 antigen (p24) Hs.114286 0.31
TNNI2 Troponin I, skeletal, fast Hs.523403 0.32
FBLN1 Fibulin 1 Hs.24601 0.32
S100A8 S100 calcium binding protein A8 (calgranulin A) Hs.416073 0.33
LOC91614 Novel 58.3 KDA protein Hs.280990 0.34
CTSL Cathepsin L Hs.418123 0.34
PRPS2 Phosphoribosyl pyrophosphate synthetase 2 Hs.104123 0.35
TMSB10 Thymosin, b 10 Hs.446574 0.37
TPM2 tropomyosin 2 (b) Hs.300772 0.37
SH3KBP1 SH3-domain kinase-binding protein 1 Hs.444770 0.38
FOSL1 FOS-like antigen 1 Hs.283565 0.39
ODC1 Ornithine decarboxylase 1 Hs.467701 0.39
MRLC2 Myosin regulatory light chain MRLC2 Hs.464472 0.39
LOC57228 Hypothetical protein from clone 643 Hs.558523 0.39
CD164 CD164 antigen, sialomucin Hs.520313 0.41
CAMK1 Calcium/calmodulin-dependent protein kinase I Hs.434875 0.41
RPA3 Replication protein A3, 14kDa Hs.487540 0.41
VIL2 Villin 2 (ezrin) Hs.487027 0.42
IFRD2 Interferon-related developmental regulator 2 Hs.315177 0.42
NLGN2 Neuroligin 2 Hs.26229 0.43
CD59 CD59 antigen p18-20 Hs.278573 0.43
ZBTB4 Zinc finger and BTB domain containing 4 Hs.35096 0.45
TXNRD1 Thioredoxin reductase 1 Hs.337766 0.46
MAT2B Methionine adenosyltransferase II, b Hs.54642 0.46
BMP1 Bone morphogenetic protein 1 Hs.1274 0.46
HRB2 HIV-1 rev binding protein 2 Hs.205558 0.47
APPBP1 Amyloid b precursor protein binding protein 1, 59kDa Hs.460978 0.48
CTNNA1 Catenin (cadherin-associated protein), a 1, 102kDa Hs.445981 0.49
COMMD6 COMM domain containing 6 Hs.508266 0.51
MAP4 Microtubule-associated protein4 Hs.517949 0.51
PSMD12 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 12 Hs.4295 0.51
PLP2 Proteolipid protein 2 (colonic epithelium-enriched) Hs.77422 0.52
GPX1 Glutathione peroxidase 1 Hs.76686 0.52
SYPL Synaptophysin-like protein Hs.80919 0.54
PICALM Phosphatidylinositol-binding clathrin assembly protein Hs.163893 0.56
PTPN12 Protein tyrosine phosphatase, non-receptor type 12 Hs.61812 0.56
PSMA5 Proteasome (prosome, macropain) subunit,a type5 Hs.485246 0.58
ST13 Suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein) Hs.546303 0.58
SR140 U2-associated SR140 protein Hs.529577 0.58
PAWR PRKC, apoptosis, WT1, regulator Hs.406074 0.59
EGR3 Early growth response 3 Hs.534313 0.60
HNRPH1 Heterogeneous nuclear ribonucleoprotein H1 (H) Hs.202166 0.60
GLTSCR2 Glioma tumour suppressor candidate region gene 2 Hs.421907 0.61
PCNA Proliferating cell nuclear antigen Hs.147433 0.61
PSMB3 Proteasome (prosome, macropain) subunit, b type, 3 Hs.82793 0.61
EMR3 Egf-like module containing, mucin-like, hormone receptor-like 3 Hs.295626 0.62
Genes significantly (Po0.007) up- or downregulated in the neuroendocrine cell lines compared with the non-neuroendocrine cell lines. The first half of the table shows
downregulated genes whereas the last part of the table shows the upregulated genes. The genes are all given with unigene cluster id’s, official gene name and symbols in addition
to their respective ratio (NE vs non-NE).
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sprogression and metastasis (MME, STAT3, DCBLD2, S100A10,
CD9, S100A8) were highly downregulated in the NE vs the non-NE
tumour group (Table 2 and Supplementary Information). The
three most highly downregulated genes in our study were MME
(0.12 fold), STAT3 (0.13) and DCBLD2 (0.14 fold). Our results also
point to differences in expression of several genes thought to be
involved in the process of tumorigenesis (BEX1, TMEPAI, FOSL1,
RAB32, ERBB2) (Table 2 and Supplementary Information). Well-
differentiated NETs are in general relatively insensitive to various
chemotheurapeutic drugs, and thus it is interesting to note
variations between the two groups in the expression of genes
known to be involved in the process of drug resistance (STAT3,
PRXD2 ABCC6, GSTP1) (Table 2 and Supplementary Information).
Nearly 50% of the upregulated, and 16% of the downregulated
genes are in the GO database defined as having an unknown
function (Supplementary Information).
Validation by real-time qRT–PCR
To validate the microarray results, we performed real-time
quantitative RT–PCR analysis of five selected genes using the
same RNA samples as those used in the microarray analysis. The
selection of the genes (BAALC, SCG2, GSTP1, FOSL1, M160) were
based upon a combination of P-value, differential expression, and
biological function. In general, 70% of the genes found to be
differentially expressed in the microarray study were confirmed by
RT–PCR (Figure 2). This seems to be in accordance with previous
studies using cDNA arrays (Kothapalli et al, 2002; Hofsli et al,
2005), and underlines the need to verify microarray data by
additional methods.
Protein expression analysis
To investigate whether the difference in gene expression level was
followed by a similar expression pattern at the protein level, we
first performed western blot analysis of cell lysates. The selection
of gene products analysed (secretogranin II, peroxiredoxin 2,
hepsin) was based upon a combination of the expression level
found in the microarray analysis, biological relevance, and
availability of antibodies. As seen in Figure 3, the protein
expression of the NE marker secretogranin II, correlated well with
the gene expression level of SCG2 found in the microarray analysis
(15-fold upregulated)(Table 2), and in the real-time RT–PCR
analysis (Figure 2). All the NE tumour cell lines express a high level
of SCG2, whereas the expression level in the non-NE cell group is
almost undetectable. Hepsin (2.8 fold upregulated in the micro-
array analysis) was found to be expressed in all cell lines and
without any significant difference in NE vs non-NE cells (Figure 3).
Thus, hepsin is ruled out as a possible new diagnostic marker of
NET disease. On the contrary, the level of peroxiredoxin 2
expression (5 fold upregulated in the microarray analysis) was
significantly different in the two groups (Figure 3). Peroxiredoxin
2 was clearly detectable in the NE cell line group, but almost
undetectable in the non-NE cell group, thus pointing out
peroxiredoxin 2 as an interesting new NE biomarker. The
difference in secretogranin II and peroxiredoxin 2 expression
was also confirmed by IHC analysis (data not shown).
In addition to secretogranin II and peroxiredoxin 2, our study
points to NEFM as another interesting candidate marker of NET
disease. NEFM, which was upregulated by a factor of 7.7 in the
microarray analysis (Table 2), was by IHC shown to be expressed
only in the NE tumour cells group (data not shown).
DISCUSSION
Although last year’s genomic and proteomic research have
uncovered some genes and gene products thought to have an
important function in the context of NE tumour biology (Hofsli,
2006), still much is unknown concerning which factors that are
important with regard to the causes and behaviours of NET
Figure 1 Hierarchical clustering analysis. A hierarchical clustering algorithm was used to cluster experimental samples on the basis of similarities of gene
expression. Relationships between the experimental samples are summarised as dendrograms, in which the pattern and length of the branches reflect the
relatedness of the samples (NE vs non-NE). Data are presented in a matrix format: each row represents a cDNA clone (identified with UniGene gene
symbol, name and IMAGE clone id) and each column an individual mRNA (average gene expression log ratio) sample of NE (BON, TT, SK-N-AS, SK-NFI,
NCI-H727, UMC-11) and non-NE (WiDr, A-172, SW480, A-427) cells. The results presented represent the ratio of hybridisation of fluorescent cDNA
probes prepared from each experimental mRNA sample to a reference mRNA sample. These ratios (log) are a measure of relative gene expression in each
experimental sample and were depicted according to the colour scale shown at the bottom.
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sdiseases. The results of this study contribute to an increased
insight into the biology of these tumours, by identifying genes that
are differentially expressed in NE tumour cells as compared with
non-NE tumour cells. We believe that some of these genes and
gene products represent interesting candidates in the search for
new prognostic, predictive and therapeutic markers. The study
also point to genes that may play a role in the tumorigenesis of
NETs.
The three most highly overexpressed genes in the NE vs the
non-NE tumour cell group (SCG3, SCG2 and DDC) (Table 2), have
all previously been described in the context of NE tumour biology,
thus confirming the reliability of our study design. Although
secretogranin II and one of its split product (Taupenot et al, 2003;
Guillemot et al, 2006) have been shown to be expressed in various
types of NETs, investigations of the expression of secretogranin III
in NETs have so far not been reported. The enzyme dopa
decarboxylase (DDC)(catecholamine biosynthesis) has more
recently been shown to be expressed in various NETs, such as
bronchial carcinoids and poorly differentiated NE carcinomas of
the lung (Uccella et al, 2006). It has also been shown to be a marker
of neuroblastoma in children (Bozzi et al, 2004), and of NE
differentiation in prostate carcinoma (Wafa et al, 2007). Another
gene known to be involved in catecholamine metabolism, MAOA
(Toninello et al, 2006), was also identified as highly expressed in
the NET group (Table 2), a finding that was confirmed by IHC
analysis (not shown). This supports previous findings demonstrat-
ing a high expression of MAOA in gastroenteropancreatic (GEP)
tumours (O ¨rlefors et al, 2003). To conclude, we believe that SCG3,
SCG2 and DDC could represent useful additional biomarkers in
NET diseases, and that they perhaps should be implemented in the
standard diagnostic panel of NE biomarkers. Furthermore,
measurement of MAOA activity may, as recently shown in a
baboon model, aid in understanding the pathophysiology of NETs
(Murthy et al, 2007).
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Figure 2 RT–PCR confirmation of microarray results. A selection of genes (A–E) was also analysed by semi quantitative real-time RT–PCR (grey), and
compared to the respective ratios of the microarray analysis (white). The two methods correlated at 9/10 cell lines at best, and the lowest correlated at
6/10 cell lines. Y axis shows the log-transformed ratio of both the microarray and the RT–PCR, based on the fold change ratios and the delta–delta Ct
calculation, respectively.
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NET biomarkers, our study points to NEFM, PRDX2, and CLDN4
as other interesting candidate markers of NET disease. The finding
of an upregulation of the NEFM gene (a marker of neuronal
differentiation) is in accordance to findings by Perez et al (1990),
who found NEFM expression in a subset of pancreatic islet cell and
rectal carcinoid tumours, although rarely in ileojejunal carcinoid
tumours. Thus, the message brought from our study and that of
Perez is, that neurofilament subtyping could well become a
potential diagnostic tool with regard to NETs.
Also the antioxidant enzyme peroxiredoxin 2 (PRXD2) (anti-
apoptosis) was highly upregulated in the NE tumour cell group.
PRXD2 was previously shown to be elevated in several human
cancers, to confer resistance to chemo- and radiation therapy, and
to promote tumour progression and metastasis (Lee et al, 2007).
The tight junction protein claudin 4 (CLDN4) is also frequently
overexpressed in several cancers, and is thought to represent a
promising target for cancer detection, diagnosis, and therapy
(Morin, 2005; Kominsky et al, 2007). A loss of claudin 4 expression
at the invasive front in colorectal cancer correlates with cancer
invasion and metastasis (Ueda et al, 2007), and thus the finding in
our study of a rather high level of CLDN4 in the NE tumour group,
may reflect NETs in general lower malignant phenotype. However,
our results are in contrast to that of Moldvay et al (2007), who
more recently have demonstrated that a majority of bronchial
carcinoids express a lower level of CLDN4 than other histological
types of primary bronchial cancers.
Several of the differentially expressed genes turned out to
have unknown functions (Supplementary Information; GEO
GSE4328). We focused on BAALC (brain and acute leukaemia,
cytoplasmic), as a high mRNA transcript level of this gene has been
found in tissues of neuroectodermal origin (Tanner et al, 2001),
and has been shown to be an independent adverse prognostic
factor in various acute leukaemias (Marcucci et al, 2005; Baldus
et al, 2007). The high expression of BAALC found in the
microarray analysis (Table 2), was confirmed by real-time PCR
analysis (Figure 2).
Our results also point to differences in expression of several
genes thought to be involved in the process of tumorigenesis
(BEX1, TMEPAI, FOSL1, RAB32, ERBB2) (Table 2; Supplementary
Information). One interesting find is the high expression of the
novel BEX1 gene (brain expressed, X-linked 1) in the NE tumour
cell group (Table 2). Previous studies have revealed a high
expression of this gene in brain, but also in peripheral organs such
as liver, pancreas, testis, and ovary (Yang et al, 2002a,b; Alvarez
et al, 2005). It has more recently been suggested that BEX1 may
play a role as a tumour suppressor in malignant glioma (Foltz et al,
2006). A very low expression was observed for the TMEPAI gene
(Table 2), which is involved in androgen receptor signaling, and is
proposed to play a role in prostate tumorigenesis (Xu et al, 2003).
TMEPAI has been shown to be overexpressed in various solid
tumours, probably because of abnormal activation of the EGF
pathway (Giannini et al, 2003). Also the oncogenic transcription
factor FOSL1, was downregulated in the NE tumour cell group.
FOSL1 is upregulated in several solid cancers, and is becoming a
new target for cancer intervention (Young and Colburn 2006). The
ras family member RAB32, has been proposed to represent a
component of the oncogenic pathway of microsatellite instability-
high gastrointestinal adenocarcinomas (Shibata et al, 2006). In our
study, RAB32 was highly downregulated in the NE vs the non-NE
group. Also the ERBB2 gene expression level was significantly
lower in the NE tumour cell group than in the non-NET group. The
expression level of this member of the oncogenic EGF receptor
family, has previously been reported as a variable in various NETs
(cf. Hofsli, 2006). So far, there is no strong evidence that ERBB2
amplification/overexpression could play an important role in NET
pathogenesis, or that it could be a potential target for treatment, as
is the case in various epithelial cancers (Hsieh and Moasser 2007).
To conclude, our study is the first to reveal the expression pattern
of BEX1, TMEPAI, FOSL1, and RAB32 in NE tumour cells, and we
believe that they represent interesting novel candidates in the
context of NET tumorigenesis.
A hallmark of NETs in general, are that they are relatively slow
growing and less invasive in character. Thus, its interesting to note
that several genes thought to play a role in the processes of
invasion, tumour progression and metastasis (MME, STAT3,
DCBLD2, S100A10, CD9, S100A8) were highly downregulated in
the NE vs the non-NE tumour group (Table 2). The most highly
downregulated gene was MME. A loss or decrease in MME has
been reported in a variety of malignancies, and reduced expression
results in the accumulation of higher peptide concentrations that
could mediate neoplastic progression (Sumitomo et al, 2005). Loss
of this endopeptidase also leads to AKT1 (protein kinase B)
activation, and contributes to the clinical progression of prostate
cancer (Osman et al, 2006). STAT3 (the signal-transducer and
activator –of transcription 3) is thought to play an important role
in both tumorigenesis and tumour progression, and is often
constitutively activated in tumour cells (Aggarwal et al, 2006).
Thus, inhibitors of STAT3 activation have potential for both
prevention and therapy of cancer (Huang, 2007). In lung cancer,
DCBLD2 has been shown to be highly upregulated in the cell line
NCI-H460-LNM35, in association with its acquisition of metastatic
phenotype, and also upregulated in high frequency in metastatic
lesions from lung cancers (Koshikawa et al, 2002). It is also shown
that DCBLD2 may play a role in cell motility (Nagai et al, 2007),
and thus it is suggested that this novel gene may become a target of
therapy to inhibit metastasis of lung cancers.
The plasminogen receptor S100A10 is found overexpressed in
many cancer cells, and seems to play an important role in cancer
cell invasiveness and metastasis (Kwon et al, 2005). RNA
interference-mediated downregulation of S100A10 gene expression
in colorectal cancer cells, has been shown to result in a complete
loss in plasminogen-dependent cellular invasiveness (Zhang et al,
2004). More recently it has been shown by IHC analysis that
S100A10 expression in thyroid neoplasms contributes to the
aggressive characteristic of anaplastic carcinoma (Ito et al, 2007).
To conclude, the very low levels of various genes known to be
involved in the processes of invasion, tumour progression and
metastasis could perhaps reflect the in general more slow growing
and less invasive character of NETs.
In addition to the already mentioned STAT3 and PRXD2, other
genes that have been linked to the phenomenon of drug resistance,
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Figure 3 Western blot. Western blot analysis was performed on cell
lines (NE and non-NE) with the antibodies against secretogranin II, hepsin,
peroxiredoxin 2 and GAPDH. Cells were harvested and prepared as
described in Materials and methods.
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differentiated NETs are in general relatively insensitive to various
chemotheurapeutic drugs. Thus, it is interesting to note that our
study reveals a relatively high expression of ABCC6 (ATP-binding
cassette, subfamily C (CFTR/MRP), member 6), one member of the
MRP subfamily involved in multi-drug resistance (Beck et al,
2005). Endocrine G-cells in the stomach has been shown to express
high level of ABCC6 (Beck et al, 2005). However, our study is the
first to report ABCC6 expression in NE tumour cells. The
antiapoptosis gene GSTP1, was highly downregulated in the NET
group (Table 2). In prostate cancer, the loss of expression of
GSTP1 is the most common genetic alteration reported (Meiers
et al, 2007). A comprehensive survey of GSTP1 expression in NETs
has so far not been performed, but one study has been undertaken,
showing that the expression of this drug-resistant protein is
significantly lower in large cell NE carcinoma of the lung than in
the other more common histological types of lung cancer (Okada
et al, 2003).
In conclusion, the results of our study add new important lights
into the understanding of NE tumour biology, by identifying genes
differentially expressed in NE as compared with non-NE tumour
cells. In addition to potential new diagnostic markers (SCG2, SCG3,
DDC, MAOA, NEFM, CLDN4, PEROX2), genes critical in the
processes of tumour invasion, progression and metastasis (MME,
STAT3, DCBLD2, S100A10, CD9, S100A8), tumorigenesis (BEX1,
TMEPAI, FOSL1, RAB32) and drug-resistance (ABCC6, GSTP1)
were identified, as well as several genes with hitherto unknown
functions.
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